Orthocell Limited (ASX: OCC)

Market Cap	306.28M
Revenue (ttm)	5.32M
Net Income (ttm)	-7.18M
Shares Out	239.28M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	765,120
Average Volume	2,011,826
Open	1.300
Previous Close	1.280
Day's Range	1.280 - 1.330
52-Week Range	0.350 - 1.660
Beta	0.75
RSI	55.70
Earnings Date	Feb 21, 2025

About Orthocell

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union. The company offers Ortho-ATI, a cell therapy for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; Remplir, a collagen scaffold used in peripheral nerve repair; and Ortho-ACI, an autologous chondr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: OCC

Financial Performance

In 2024, Orthocell's revenue was 5.32 million, an increase of 25.27% compared to the previous year's 4.24 million. Losses were -7.18 million, 14.9% more than in 2023.